A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Summary

This study aims to evaluate the safety, tolerability and effectiveness of BTA798 on * shortening the length and reducing the symptoms of human rhinovirus infection (also known as the common cold), * controlling asthma symptoms, and * lowering the risk of asthma symptoms worsening in subjects with asthma.

Timeline

Start

2010-08

Primary completion

2012-03

Completion

2012-03

Outcome

Met primary endpoint

registry LEAST_SQUARES_MEAN BTA798: -9.12 (Standard Error 1.403) Scores on a scale NCT01175226 ↗

registry analysis (superiority test); BTA798 vs Placebo; p = 0.020; ANCOVA NCT01175226 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vapendavir	Small molecule	—	—

Indications